Retraction: Chronic inflammation: Accelerator of biological aging (Journals of Gerontology - Series A Biological Sciences and Medical Sciences DOI: 10.1093/gerona/glw240);Chronic inflammation: Accelerator of biological aging

Journals of Gerontology - Series A Biological Sciences and Medical Sciences

Volumn 72, Issue 9, 2017, Pages 1218-1225

  Fougère, Bertrand ^a,b   Boulanger, Eric ^c   Nourhashémi, Fati ^a,b   Guyonnet, Sophie ^a,b   Cesari, Matteo ^a,b  

^a TOULOUSE UNIVERSITY HOSPITAL   (France)

^b UNIVERSITÉ PAUL SABATIER   (France)

^c UNIV LILLE   (France)

Author keywords

Aging; Biology; Chronic diseases; Inflammation

Indexed keywords

BIOLOGICAL MARKER;

AGING; CHRONIC DISEASE; HUMAN; INFLAMMATION; MORBIDITY; PATHOPHYSIOLOGY; PHYSIOLOGY; RISK FACTOR;

AGING; BIOMARKERS; CHRONIC DISEASE; HUMANS; INFLAMMATION; MORBIDITY; RISK FACTORS;

EID: 85028329928     PISSN: 10795006     EISSN: 1758535X     Source Type: Journal    
DOI: 10.1093/gerona/gly284     Document Type: Erratum

References (98)

1. Burton DGA. Cellular senescence, ageing and disease. Age Dordr Neth. 2009;31(1):1–9.
2. Ren JL, Pan JS, Lu YP, Sun P, Han J. Inflammatory signaling and cellular senescence. Cell Signal. 2009;21:378–383. doi:10.1016/j. cellsig.2008.10.011
3. Baylis D, Bartlett DB, Patel HP, Roberts HC. Understanding how we age: insights into inflammaging. Longev Healthspan. 2013;2:8. doi:10.1186/2046-2395-2-8
4. Franceschi C, Capri M, Monti D, et al. Inflammaging and anti-inflammaging: a systemic perspective on aging and longevity emerged from studies in humans. Mech Ageing Dev. 2007;128(1):92–105.
5. Gabay C, Kushner I. Acute-phase proteins and other systemic responses to inflammation. N Engl J Med. 1999;340:448–454. doi:10.1056/ NEJM199902113400607
6. Tracy RP. Emerging relationships of inflammation, cardiovascular disease and chronic diseases of aging. Int J Obes Relat Metab Disord. 2003;27(suppl 3):S29–S34. doi:10.1038/sj.ijo.0802497
7. Singh T, Newman AB. Inflammatory markers in population studies of aging. Ageing Res Rev. 2011;10:319–329. doi:10.1016/j.arr.2010.11.002
8. Chung HY, Cesari M, Anton S, et al. Molecular inflammation: underpinnings of aging and age-related diseases. Ageing Res Rev. 2009;8:18–30. doi:10.1016/j.arr.2008.07.002
9. Rassaf T, Bryan NS, Maloney RE, et al. NO adducts in mammalian red blood cells: too much or too little? Nat Med. 2003;9:481–482. doi:10.1038/nm0503-481.
10. De la Fuente M. Effects of antioxidants on immune system ageing. Eur J Clin Nutr. 2002;56(suppl 3):S5–S8.
11. Maillard L. Action des acides amines sur les sucres; formation des mela-noidines par voie methodique. C R Acad Sci. 1912;154:66–68.
12. Ott C, Jacobs K, Haucke E, Navarrete Santos A, Grune T, Simm A. Role of advanced glycation end products in cellular signaling. Redox Biol. 2014;2:411–429. doi:10.1016/j.redox.2013.12.016
13. Boulanger E, Wautier MP, Wautier JL, et al. AGEs bind to mesothelial cells via RAGE and stimulate VCAM-1 expression. Kidney Int. 2002;61:148–156. doi:10.1046/j.1523-1755.2002.00115.x
14. Roca F, Grossin N, Chassagne P, Puisieux F, Boulanger E. Glycation: the angiogenic paradox in aging and age-related disorders and diseases. Ageing Res Rev. 2014;15:146–160. doi:10.1016/j.arr.2014.03.009
15. Grossin N, Auger F, Niquet-Leridon C, et al. Dietary CML-enriched protein induces functional arterial aging in a RAGE-dependent manner in mice. Mol Nutr Food Res. 2015;59:927–938. doi:10.1002/mnfr.201400643
16. Bender A, Krishnan KJ, Morris CM, et al. High levels of mitochondrial DNA deletions in substantia nigra neurons in aging and Parkinson disease. Nat Genet. 2006;38:515–517. doi:10.1038/ng1769
17. Green DR, Galluzzi L, Kroemer G. Mitochondria and the autophagy-inflammation-cell death axis in organismal aging. Science. 2011;333:1109–1112. doi:10.1126/science.1201940
18. Boots AM, Maier AB, Stinissen P, Masson P, Lories RJ, De Keyser F. The influence of ageing on the development and management of rheumatoid arthritis. Nat Rev Rheumatol. 2013;9:604–613. doi:10.1038/nrrheum.2013.92
19. Weyand CM, Fulbright JW, Goronzy JJ. Immunosenescence, autoimmunity, and rheumatoid arthritis. Exp Gerontol. 2003;38:833–841.
20. Derhovanessian E, Maier AB, Hähnel K, et al. Infection with cytomegalovirus but not herpes simplex virus induces the accumulation of late-differentiated CD4+ and CD8+ T-cells in humans. J Gen Virol. 2011;92(pt 12):2746–2756. doi:10.1099/vir.0.036004-0
21. Roberts ET, Haan MN, Dowd JB, Aiello AE. Cytomegalovirus antibody levels, inflammation, and mortality among elderly Latinos over 9 years of follow-up. Am J Epidemiol. 2010;172:363–371. doi:10.1093/aje/kwq177
22. Zapata HJ, Shaw AC. Aging of the human innate immune system in HIV infection. Curr Opin Immunol. 2014;29:127–136. doi:10.1016/j. coi.2014.06.007
23. Lederman MM, Funderburg NT, Sekaly RP, Klatt NR, Hunt PW. Residual immune dysregulation syndrome in treated HIV infection. Adv Immunol. 2013;119:51–83. doi:10.1016/B978-0-12-407707-2.00002-3
24. Oppermann RV, Weidlich P, Musskopf ML. Periodontal disease and systemic complications. Braz Oral Res. 2012;26(suppl 1):39–47.
25. Wade WG. The oral microbiome in health and disease. Pharmacol Res. 2013;69:137–143. doi:10.1016/j.phrs.2012.11.006
26. Luz C, Dornelles F, Preissler T, Collaziol D, da Cruz IM, Bauer ME. Impact of psychological and endocrine factors on cytokine production of healthy elderly people. Mech Ageing Dev. 2003;124:887–895.
27. Bauer ME, Jeckel CM, Luz C. The role of stress factors during aging of the immune system. Ann N Y Acad Sci. 2009;1153:139–152. doi:10.1111/j.1749-6632.2008.03966.x
28. Migeon CJ, Keller AR, Lawrence B, Shepard TH II. Dehydroepiandrosterone and androsterone levels in human plasma: effect of age and sex; day-today and diurnal variations. J Clin Endocrinol Metab. 1957;17:1051–1062. doi:10.1210/jcem-17-9-1051
29. Traish AM, Kang HP, Saad F, Guay AT. Dehydroepiandrosterone(DHEA)—a precursor steroid or an active hormone in human physiology. J Sex Med. 2011;8:2960–2982; quiz 2983. doi:10.1111/j.1743-6109.2011.02523.x
30. Keller ET, Chang C, Ershler WB. Inhibition of NFkappaB activity through maintenance of IkappaBalpha levels contributes to dihydrotestoster-one-mediated repression of the interleukin-6 promoter. J Biol Chem. 1996;271:26267–26275.
31. Tchkonia T, Morbeck DE, Von Zglinicki T, et al. Fat tissue, aging, and cellular senescence. Aging Cell. 2010;9:667–684. doi:10.1111/j.1474-9726.2010.00608.x
32. Grant RW, Dixit VD. Mechanisms of disease: inflammasome activation and the development of type 2 diabetes. Front Immunol. 2013;4:50. doi:10.3389/fimmu.2013.00050
33. Coelho M, Oliveira T, Fernandes R. Biochemistry of adipose tissue: an endocrine organ. Arch Med Sci. 2013;9:191–200. doi:10.5114/ aoms.2013.33181
34. Weisberg SP, Hunter D, Huber R, et al. CCR2 modulates inflammatory and metabolic effects of high-fat feeding. J Clin Invest. 2006;116:115–124 doi:10 1172/JCI24335
35. Galic S, Oakhill JS, Steinberg GR. Adipose tissue as an endocrine organ. Mol Cell Endocrinol. 2010;316:129–139. doi:10.1016/j.mce.2009.08.018
36. Bochud M, Marquant F, Marques-Vidal PM, et al. Association between C-reactive protein and adiposity in women. J Clin Endocrinol Metab. 2009;94:3969–3977. doi:10.1210/jc.2008-2428
37. Mortensen OH, Nielsen AR, Erikstrup C, et al. Calprotectin—a novel marker of obesity. PLoS One. 2009;4:e7419. doi:10.1371/journal. pone.0007419
38. Giugliano D, Ceriello A, Esposito K. The effects of diet on inflammation: emphasis on the metabolic syndrome. J Am Coll Cardiol. 2006;48:677–685. doi:10.1016/j.jacc.2006.03.052
39. Lopez-Garcia E, Schulze MB, Fung TT, et al. Major dietary patterns are related to plasma concentrations of markers of inflammation and endothelial dysfunction. Am J Clin Nutr. 2004;80:1029–1035.
40. Lopez-Garcia E, Schulze MB, Meigs JB, et al. Consumption of trans fatty acids is related to plasma biomarkers of inflammation and endothelial dysfunction. J Nutr. 2005;135:562–566.
41. Mozaffarian D, Aro A, Willett WC. Health effects of trans-fatty acids: experimental and observational evidence. Eur J Clin Nutr. 2009;63(suppl 2):S5–S21. doi:10.1038/sj.ejcn.1602973
42. Benigni A, Cassis P, Remuzzi G. Angiotensin II revisited: new roles in inflammation, immunology and aging. EMBO Mol Med. 2010;2:247–257. doi:10.1002/emmm.201000080
43. Abadir PM, Walston JD, Carey RM, Siragy HM. Angiotensin II Type-2 receptors modulate inflammation through signal transducer and activator of transcription proteins 3 phosphorylation and TNFα production. J Interferon Cytokine Res. 2011;31:471–474. doi:10.1089/jir.2010.0043
44. Shah PP, Donahue G, Otte GL, et al. Lamin B1 depletion in senescent cells triggers large-scale changes in gene expression and the chromatin landscape. Genes Dev. 2013;27:1787–1799. doi:10.1101/ gad.223834.113
45. Fougère B, Vellas B, Billet S, Martin PJ, Gallucci M, Cesari M. Air pollution modifies the association between successful and pathological aging throughout the frailty condition. Ageing Res Rev. 2015;24(pt B):299–303. doi:10.1016/j.arr.2015.09.004
46. Grivennikov SI, Karin M. Inflammation and oncogenesis: a vicious connection. Curr Opin Genet Dev. 2010;20:65–71. doi:10.1016/j. gde.2009.11.004
47. Franceschi C, Bonafè M, Valensin S, et al. Inflamm-aging. An evolutionary perspective on immunosenescence. Ann N Y Acad Sci. 2000;908:244–254.
48. Franceschi C, Campisi J. Chronic inflammation (inflammaging) and its potential contribution to age-associated diseases. J Gerontol A Biol Sci Med Sci. 2014;69(suppl 1):S4–S9. doi:10.1093/gerona/glu057
49. Coppé JP, Desprez PY, Krtolica A, Campisi J. The senescence-associated secretory phenotype: the dark side of tumor suppression. Annu Rev Pathol. 2010;5:99–118. doi:10.1146/annurev-pathol-121808-102144
50. Coppé JP, Patil CK, Rodier F, et al. Senescence-associated secretory phenotypes reveal cell-nonautonomous functions of oncogenic RAS and the p53 tumor suppressor. PLoS Biol. 2008;6:2853–2868. doi:10.1371/journal. pbio.0060301
51. Aubert G, Lansdorp PM. Telomeres and aging. Physiol Rev. 2008;88:557–579. doi:10.1152/physrev.00026.2007
52. O’Donovan A, Pantell MS, Puterman E, et al.; Health Aging and Body Composition Study. Cumulative inflammatory load is associated with short leukocyte telomere length in the Health, Aging and Body Composition Study. PLoS One. 2011;6:e19687. doi:10.1371/journal.pone.0019687
53. Libby P, Ridker PM, Hansson GK; Leducq Transatlantic Network on Atherothrombosis. Inflammation in atherosclerosis: from pathophysiology to practice. J Am Coll Cardiol. 2009;54:2129–2138. doi:10.1016/j. jacc.2009.09.009
54. Harrison DG, Guzik TJ, Lob HE, et al. Inflammation, immunity, and hypertension. Hypertension. 2011;57:132–140. doi:10.1161/ HYPERTENSIONAHA.110.163576
55. Dawood T, Schlaich MP. Mediators of target organ damage in hypertension: focus on obesity associated factors and inflammation. Minerva Cardioangiol. 2009;57:687–704.
56. Ridker PM, Cushman M, Stampfer MJ, Tracy RP, Hennekens CH. Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men. N Engl J Med. 1997;336:973–979. doi:10.1056/ NEJM199704033361401
57. Conen D, Ridker PM, Everett BM, et al. A multimarker approach to assess the influence of inflammation on the incidence of atrial fibrillation in women Eur Heart J 2010 31:1730–1736 doi:10 1093/eurheartj/eh 146
58. Coussens LM, Werb Z. Inflammation and cancer. Nature. 2002;420:860–867. doi:10.1038/nature01322
59. Shacter E, Weitzman SA. Chronic inflammation and cancer. Oncol Williston Park N. 2002;16(2):217–226, 229–232.
60. Hussain SP, Hofseth LJ, Harris CC. Radical causes of cancer. Nat Rev Cancer. 2003;3:276–285. doi:10.1038/nrc1046
61. Allavena P, Garlanda C, Borrello MG, Sica A, Mantovani A. Pathways connecting inflammation and cancer. Curr Opin Genet Dev. 2008;18:3–10. doi:10.1016/j.gde.2008.01.003
62. Mantovani A, Romero P, Palucka AK, Marincola FM. Tumour immunity: effector response to tumour and role of the microenvironment. Lancet. 2008;371:771–783. doi:10.1016/S0140-6736(08)60241-X
63. Szlosarek PW, Balkwill FR. Tumour necrosis factor alpha: a potential tar get for the therapy of solid tumours. Lancet Oncol. 2003;4:565–573.
64. Subbaramaiah K, Dannenberg AJ. Cyclooxygenase 2: a molecular target for cancer prevention and treatment. Trends Pharmacol Sci. 2003;24:96–102. doi:10.1016/S0165-6147(02)00043-3
65. Caruso C, Balistreri CR, Crivello A, et al. The genetics of innate immunity and inflammation in ageing, age-related diseases and longevity. In: Immunosenescence. New York: Springer; 2007. p. 154–73. (Medical Intelligence Unit). http://link.springer.com/chapter/10.1007/978-0-387-76842-7_14. Accessed February 24, 2016.
66. Stuart MJ, Baune BT. Depression and type 2 diabetes: inflammatory mechanisms of a psychoneuroendocrine co-morbidity. Neurosci Biobehav Rev. 2012;36:658–676. doi:10.1016/j.neubiorev.2011.10.001
67. Pickup JC. Inflammation and activated innate immunity in the pathogenesis of type 2 diabetes. Diabetes Care. 2004;27:813–823.
68. Hogue JC, Lamarche B, Tremblay AJ, Bergeron J, Gagné C, Couture P. Differential effect of atorvastatin and fenofibrate on plasma oxidized low-density lipoprotein, inflammation markers, and cell adhesion molecules in patients with type 2 diabetes mellitus. Metabolism. 2008;57:380–386. doi:10.1016/j.metabol.2007.10.014
69. Wallin R, Wajih N, Greenwood GT, Sane DC. Arterial calcification: a review of mechanisms, animal models, and the prospects for therapy. Med Res Rev. 2001;21:274–301.
70. Hirose K, Tomiyama H, Okazaki R, et al. Increased pulse wave velocity associated with reduced calcaneal quantitative osteo-sono index: possible relationship between atherosclerosis and osteopenia. J Clin Endocrinol Metab. 2003;88:2573–2578. doi:10.1210/jc.2002-021511
71. Manolagas SC. Birth and death of bone cells: basic regulatory mechanisms and implications for the pathogenesis and treatment of osteoporosis. Endocr Rev. 2000;21:115–137. doi:10.1210/edrv.21.2.0395
72. Moffett SP, Zmuda JM, Oakley JI, et al. Tumor necrosis factor-alpha polymorphism, bone strength phenotypes, and the risk of fracture in older women. J Clin Endocrinol Metab. 2005;90:3491–3497. doi:10.1210/ jc.2004-2235
73. Toth MJ, Ades PA, Tischler MD, Tracy RP, LeWinter MM. Immune activation is associated with reduced skeletal muscle mass and physical function in chronic heart failure. Int J Cardiol. 2006;109:179–187. doi:10.1016/j. ijcard.2005.06.006
74. Visser M, Pahor M, Taaffe DR, et al. Relationship of interleukin-6 and tumor necrosis factor-alpha with muscle mass and muscle strength in elderly men and women: the Health ABC Study. J Gerontol A Biol Sci Med Sci. 2002;57:M326–M332.
75. Schaap LA, Pluijm SM, Deeg DJ, Visser M. Inflammatory markers and loss of muscle mass (sarcopenia) and strength. Am J Med. 2006;119:526. e9–526.e17. doi:10.1016/j.amjmed.2005.10.049
76. Schaap LA, Pluijm SM, Deeg DJ, et al.; Health ABC Study. Higher inflammatory marker levels in older persons: associations with 5-year change in muscle mass and muscle strength. J Gerontol A Biol Sci Med Sci. 2009;64:1183–1189. doi:10.1093/gerona/glp097
77. Frost RA, Lang CH. Protein kinase B/Akt: a nexus of growth factor and cytokine signaling in determining muscle mass. J Appl Physiol (1985). 2007;103:378–387. doi:10.1152/japplphysiol.00089.2007
78. Puthucheary ZA, Rawal J, McPhail M, et al. Acute skeletal muscle wasting in critical illness. JAMA. 2013;310:1591–1600. doi:10.1001/ jama.2013.278481
79. Zoico E, Corzato F, Bambace C, et al. Myosteatosis and myofibrosis: relationship with aging, inflammation and insulin resistance. Arch Gerontol Geriatr. 2013;57:411–416. doi:10.1016/j.archger.2013.06.001
80. Ahmed T, Haboubi N. Assessment and management of nutrition in older people and its importance to health. Clin Interv Aging. 2010;5:207–216.
81. Wang H, Zhou M, Brand J, Huang L. Inflammation activates the interferon signaling pathways in taste bud cells. J Neurosci. 2007;27:10703–10713. doi:10.1523/JNEUROSCI.3102-07.2007
82. Fried LP, Xue QL, Cappola AR, et al. Nonlinear multisystem physiological dysregulation associated with frailty in older women: implications for etiology and treatment. J Gerontol A Biol Sci Med Sci. 2009;64:1049–1057. doi:10.1093/gerona/glp076
83. Reiner AP, Aragaki AK, Gray SL, et al. Inflammation and thrombosis biomarkers and incident frailty in postmenopausal women. Am J Med. 2009;122:947–954. doi:10.1016/j.amjmed.2009.04.016
84. Matheï C, Vaes B, Wallemacq P, Degryse J. Associations between cytomegalovirus infection and functional impairment and frailty in the BELFRAIL Cohort. J Am Geriatr Soc. 2011;59:2201–2208. doi:10.1111/j.1532-5415.2011.03719.x
85. Barzilay JI, Blaum C, Moore T, et al. Insulin resistance and inflammation as precursors of frailty: the Cardiovascular Health Study. Arch Intern Med. 2007;167:635–641. doi:10.1001/archinte.167.7.635
86. Hubbard RE, O’Mahony MS, Savva GM, Calver BL, Woodhouse KW. Inflammation and frailty measures in older people. J Cell Mol Med. 2009;13(9B):3103–3109. doi:10.1111/j.1582-4934.2009.00733.x
87. Wu IC, Shiesh SC, Kuo PH, Lin XZ. High oxidative stress is correlated with frailty in elderly chinese. J Am Geriatr Soc. 2009;57:1666–1671. doi:10.1111/j.1532-5415.2009.02392.x
88. Bandeen-Roche K, Walston JD, Huang Y, Semba RD, Ferrucci L. Measuring systemic inflammatory regulation in older adults: evidence and utility. Rejuvenation Res. 2009;12:403–410. doi:10.1089/ rej.2009.0883
89. Serviddio G, Romano AD, Greco A, et al. Frailty syndrome is associated with altered circulating redox balance and increased markers of oxidative stress. Int J Immunopathol Pharmacol. 2009;22:819–827.
90. Koyama A, O’Brien J, Weuve J, Blacker D, Metti AL, Yaffe K. The role of peripheral inflammatory markers in dementia and Alzheimer’s disease: a meta-analysis. J Gerontol A Biol Sci Med Sci. 2013;68:433–440. doi:10.1093/gerona/gls187
91. Chi GC, Fitzpatrick AL, Sharma M, Jenny NS, Lopez OL, DeKosky ST. Inflammatory biomarkers predict domain-specific cognitive decline in older adults. J Gerontol A Biol Sci Med Sci. 2016.
92. Jefferson AL, Massaro JM, Wolf PA, et al.Inflammatorybiomarkersareasso-ciated with total brain volume: the Framingham Heart Study. Neurology. 2007;68:1032–1038. doi:10.1212/01.wnl.0000257815.20548.df
93. Eagan DE, Gonzales MM, Tarumi T, Tanaka H, Stautberg S, Haley AP. Elevated serum C-reactive protein relates to increased cerebral myoinositol levels in middle-aged adults. Cardiovasc Psychiatry Neurol. 2012;2012:120540. doi:10.1155/2012/120540
94. Marsland AL, Gianaros PJ, Abramowitch SM, Manuck SB, Hariri AR. Interleukin-6 covaries inversely with hippocampal grey matter volume in middle-aged adults. Biol Psychiatry. 2008;64:484–490. doi:10.1016/j. biopsych.2008.04.016
95. Perry VH, Cunningham C, Holmes C. Systemic infections and inflammation affect chronic neurodegeneration. Nat Rev Immunol. 2007;7:161–167. doi:10.1038/nri2015
96. Licastro F, Candore G, Lio D, et al. Innate immunity and inflammation in ageing: a key for understanding age-related diseases. Immun Ageing. 2005;2:8. doi:10.1186/1742-4933-2-8
97. Sareila O, Kelkka T, Pizzolla A, Hultqvist M, Holmdahl R. NOX2 complex-derived ROS as immune regulators. Antioxid Redox Signal. 2011;15:2197–2208. doi:10.1089/ars.2010.3635
98. Tchkonia T, Zhu Y, van Deursen J, Campisi J, Kirkland JL. Cellular senescence and the senescent secretory phenotype: therapeutic opportunities. J Clin Invest. 2013;123:966–972. doi:10.1172/ JCI64098